The Surface, Issue #8 is now available! This month we feature publications on a variety of dermatologic disorders, including melanoma and non-melanoma skin cancer, warts, nail psoriasis, and atopic dermatitis. The Surface was emailed to all PSOLVE+ members on Tues, Nov 23 and can be read online here.

The Surface Issue #8, November 2021 edition, was sent to all PSOLVE+ members by email on Tuesday, Nov 23, and can be accessed online here. This edition covers:

  • Intralesional injections of Candida antigen and bivalent HPV vaccine for common wart treatment
  • Consensus panel exercise on the practical management of AD with dupilumab
    Intramatricial secukinumab injections for patients with nail psoriasis
  • Reflexive BRAF mutational testing for suspected advanced melanoma
  • Relative risk of skin cancers with different thiazides and thiazide-like diuretics

To view all issues of The Surface, go to psolve.org/the-surface

Drs. Chi-ho Hong and Mark Kirchhof discuss the Editor’s Picks, as well as emerging therapies presented at EADV 2021 [Video 15 min]

In this 15-minute video, Dr. Chi-ho Hong and Dr. Mark Kirchhof review the Editor’s Picks, as well as emerging therapies presented at EADV 2021. What did you think were the most impactful sessions at this year’s EADV conference?


>> View the video [15 min 17 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

Drs. Mark Kirchhof and Jon Levy discuss 36-month results from the PURE registry as presented at the 30th EADV Congress [Video 6 min]

In a real-world setting, is there a correspondence of physician-led disease severity assessments with patient-reported disease severity and impact assessments in patients with moderate-to-severe plaque psoriasis treated with secukinumab? Dr. Mark Kirchhof and Dr. Jon Levy on the 36-month results from the PURE registry as presented at EADV 2021.


>> View the video [5 min 43 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

Drs. Chih-ho Hong and Gurbir Dhadwal discuss 52-week efficacy results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials as presented at the 30th EADV Congress [Video 5 min]

What impact will the novel oral therapy, deucravacitinib, have on the treatment landscape of patients with plaque psoriasis? Dr. Chih-ho Hong and Dr. Gurbir Dhadwal discuss the 52-week efficacy results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials as presented at the 30th EADV Congress.


>> View the video [4 min 42 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

Drs. Chih-ho Hong and Jessica Asgarpour present highlights from the Hidradenitis Suppurativa Symposium at the 30th EADV Congress [Video 5 min]

What is the role of multi-disciplinary care in the management of hidradenitis suppurativa? What are the latest advances in terms of pharmacological and surgical interventions? Dr. Chi-ho Hong and Dr. Jessica Asgarpour present highlights from the Hidradenitis Suppurativa Symposium at the 30th EADV Congress.


>> View the video [5 min 28 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

Dr. Jordana Schachter presents hot topics from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 28 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #7, Dr. Jordana Schachter from Montreal, Quebec, presents a 28-minute video update from the 2021 AAD VMX.


>> View the video [28 min]

* Video is in English. Voir la vidéo en français ci-dessous.

Topics reviewed in this video include:

  • What’s new in melanoma?
  • What’s new in atopic dermatitis?
  • What’s new in acne?
  • What’s new in alopecia?
  • What’snewin sunscreens?
  • What’s new in dysbiosis and inflammation?
  • What’s new in cosmeceuticals?
  • What’s new in cosmetic surgery?

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 7, la Dre Jordana Schachter (Montréal, QC) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.

>> Voir la vidéo [34 min]

* Vidéo en français. See link to English video above.

Les sujets de cette vidéo incluent :

  • Quelles sont les nouveautés en matière de mélanome?
  • Quelles sont les nouveautés en matière de dermatite atopique?
  • Quelles sont les nouveautés en matière d’acné?
  • Quelles sont les nouveautés en matière d’alopécie?
  • Quelles sont les nouveautés en matière d’écrans solaires?
  • Quelles sont les nouveautés en matière de dysbiose et d’inflammation?
  • Quelles sont les nouveautés en matière de cosméceutique?
  • Quelles sont les nouveautés en matière de chirurgie esthétique?

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.

Dr. Sophia Colantonio presents highlights from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 10 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #6, Dr. Sophia Colantonio from Ottawa, Ontario, presents a 10-minute video update from the 2021 AAD VMX.


>> View the video [10 min]

Video is in English with French subtitles.

Topics reviewed in this video include:

  • Why should the complexity of predicting psoriatic arthritis development in patients with psoriasis lead to an early and aggressive treatment?
  • How might new data in treating skin and joint manifestations of psoriatic disease influence the patient journey?
  • How can sustained improvements in nail psoriasis in a broad group of patients with psoriasis or PsA help patient adherence? 

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 6, la Dre Sophia Colantonio (Ottawa, Ontario) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.

>> Voir la vidéo [10 min]

* Vidéo en anglais avec sous-titres français.

Les sujets de cette vidéo incluent :

  • Pourquoi la difficulté de prédire si les patients atteints de psoriasis seront également touchés par la  polyarthrite psoriasique devrait-elle conduire à un traitement précoce et agressif?
  • De quelle façon les nouvelles données sur le traitement des manifestations cutanées et articulaires du  psoriasis peuvent-elles influencer le parcours du patient?
  • Comment des améliorations durables du psoriasis des ongles dans un large groupe de patients  atteints de psoriasis ou de polyarthrite psoriasique peuvent-elles favoriser le respect du traitement? 

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.

Dr. Dominique Fausto de Souza presents highlights from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 13 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #5, Dr. Dominique Fausto de Souza from Montreal, Quebec, presents a 13-minute video update from the 2021 AAD VMX.


>> View the video [13 min]

Video is in English. Voir la vidéo en français ci-dessous.

Topics reviewed in this video include:

  • What impact does emerging clinical data have on the management of plaque psoriasis?
  • Should we consider re-treatment with a biologic therapy following drug withdrawal and/or relapse?
  • Are there any new safety signals from trials with biologic therapies?

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 5, la Dre Dominique Fausto de Souza (Montréal, QC) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.

>> Voir la vidéo [13 min]

* Vidéo en français. See link to English video above.

Les sujets de cette vidéo incluent :

  • Quel est l’impact des nouvelles données cliniques sur la prise en charge du psoriasis en plaques?
  • Doit-on envisager un nouveau traitement par thérapie biologique après un arrêt du traitement ou une  rechute?
  • Y a-t-il de nouveaux signaux d’innocuité provenant des essais sur les thérapies biologiques? 

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.

The Surface, Issue #7 is now available! This month we feature five recent publications with high clinical relevance for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Tues, Sep 28 and can be read online here.

The Surface Issue #7, October 2021 edition, was sent to all PSOLVE+ members by email on Tuesday, Sep 28, and can be accessed online here. This edition covers:

  • Concomitant PsA and PsO results from the EXCEED study
  • Risk of drug exposure in PsO patients on COVID-19 outcomes in France
  • Treatment of PsO and the natural history of PsA
  • PASI-HD – a solution for BSA <10%
  • Survey on the potential impact of a biomarker patch in PsO treatment selection

To view all issues of The Surface, go to psolve.org/the-surface

Dr. Michael Cecchini presents highlights from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 12 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #4, Dr. Michael Cecchini from Richmond Hill, Ontario, presents a 12-minute video update from the 2021 AAD VMX.


>> View the video [12 min]

Video is in English with French subtitles.

Topics reviewed in this video include:

  • What new options are emerging in the treatment landscape for psoriasis?
  • How should we manage biologic therapies in patients with psoriasis and obesity?
  • Are the current treatment approaches for pediatric psoriasis patients sufficient?
  • Can children with psoriasis be safely treated with biologic therapies? 

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 4, le Dr Michael Cecchini (Richmond Hill, Ontario) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.

>> Voir la vidéo [12 min]

* Vidéo en anglais avec sous-titres français.

Les sujets de cette vidéo incluent :

  • Quelles sont les nouvelles options émergentes dans le cadre de traitements du psoriasis?
  • Comment adapter les thérapies biologiques chez les patients atteints de psoriasis et d’obésité?
  • Les approches thérapeutiques actuelles pour les patients atteints de psoriasis pédiatrique sont-elles suffisantes?
  • L’utilisation d’un traitement biologique pour traiter les enfants atteints de psoriasis est-elle sécuritaire? 

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.